GlassScriptPhysician profile
Charmain C John
NPI 1598196925
$5,368.57
in general payments reported to CMS, 2019-2025
33 companies · $921 in 2025
The $921 reported for 2025 was more than what 85% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $312 · 2022: $1,351 · 2023: $1,334 · 2024: $1,450 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,704.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $764.71 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $634.15 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $454.33 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $433.55 | 2021-2025 | |
| Glaxosmithkline, LLC. | $359.05 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $352.05 | 2022-2024 | |
| Amgen INC. | $343.90 | 2022-2025 | Repatha, Otezla, Krystexxa |
| Janssen Pharmaceuticals, INC | $324.97 | 2021-2024 | Spravato |
| Exact Sciences Corporation | $300.23 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $139.26 | 2023-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.79 | 2022-2025 | Jardiance |
| Pfizer INC. | $107.91 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $98.50 | 2022-2024 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $91.49 | 2024-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.25 | 2023-2025 | Xifaxan, Trulance |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $77.79 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $77.48 | 2022-2024 | Quviviq |
| Dynavax Technologies Corporation | $69.59 | 2022-2025 | Heplisav-B |
| Otsuka America Pharmaceutical, INC. | $67.69 | 2022-2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $66.21 | 2021-2022 | |
| Daiichi Sankyo INC. | $59.49 | 2022-2023 | Injectafer |
| Axsome Therapeutics, INC. | $44.82 | 2024-2025 | Auvelity |
| Tolmar, INC. | $43.85 | 2023-2025 | Jatenzo |
| Novartis Pharmaceuticals Corporation | $38.49 | 2022-2023 | |
| Shield Therapeutics INC | $33.88 | 2025 | |
| Amarin Pharma, INC. | $33.87 | 2022 | |
| Dexcom, INC. | $27.76 | 2024 | Dexcom G6 Transmitter |
| Corium, LLC | $26.90 | 2023 | Azstarys |
| Phadia US INC. | $21.68 | 2024 | Immunocap |
| Inspire Medical Systems, INC. | $20.57 | 2023 | Inspire |
| Jazz Pharmaceuticals INC. | $20.49 | 2022 | |
| Scilex Pharmaceuticals INC. | $19.48 | 2023 | Ztlido |
| Hikma Pharmaceuticals USA | $16.39 | 2025 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charmain John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.